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Summary Twelve patients undergoing IL-2 and flavone acetic acid (FAA) combination immunotherapy for
advanced melanoma were studied throughout treatment for the induction of measurable levels of bioactive
TNF, GM-CSF and IL-6 in their serum. This was to assess the extent of secondary cytokine induction in these
patients and the possible role of such cytokines in both the toxic and therapeutic responses. The nature of the
treatment schedule enabled these cytokines to be measured in response to FAA alone, FAA/IL-2 and FAA
alone following IL-2/FAA activation of target cells. A small rise in the serum levels of these cytokines was
seen on the initial course of FAA/IL-2 but this was minor compared to the marked elevation in levels 2-8 h
following the initiation of the third course of FAA given with or without IL-2 and at a time point which
coincided with maximum toxicity in those patients who experienced it. These results show that FAA alone can
induce cytokine release from primed target cells. This may be associated with the therapeutic effect and/or
toxicity of the agent.
The mechanisms of the anti-tumour action of biological re-
sponse modifiers include stimulus to differentiation, direct
cytotoxicity, impairment of tumour blood flow and stimula-
tion of the immune response. The response may result from
direct effect or via induction of intermediary molecules in-
cluding cytokines (see Haworth & Feldmann 1991).
IL-2 has been demonstrated to have anti-tumour effect on
a variety of solid tumours -especially renal carcinomas and
melanomas (Rosenberg et al., 1987). This action has been
attributed to the induction of large numbers of non MHC
restricted activated lymphocytes, termed lymphokine
activated killer (LAK) cells. In addition IL-2 stimulates
cytokine production by activated T cells and to a lesser
extent monocytes and may activate other cells via these
intermediaries. This may be important in the overall
therapeutic effect and in the toxicity experienced in these
regimes. It has been postulated by some, that tumour nec-
rosis factor (TNFa) may be important in the aetiology of the
capillary leak syndrome (Fraker et al., 1989) but not by
others (Ferro et al., 1989; Harms et al., 1989).
Flavone acetic acid (FAA) has been demonstrated to be
effective as an anti-tumour agent in mice but not in man (see
Cummings & Smyth, 1989 and Bibby, 1991 for reviews). It
has been classified as a biological response modifier based on
the following criteria: (1) it has been shown to induce NK
cell activity (Urba et al., 1988) (2) it induces the production
of a interferon (Havsteen, 1983) and (3) it is synergistic with
IL-2 in the treatment of murine renal carcinoma (Wiltrout et
al., 1988).
As part of a Phase I/11 study of IL-2 and FAA in meta-
static melanoma serum cytokine levels were monitored
throughout treatment. We assayed GM-CSF, IL-6, IL-1 and
TNF; cytokines which from previous experience have been
associated with systemic toxicity when given therapeutically
or had been implicated in the pathogenesis of shock (Grau et
al., 1987; Tracey et al., 1987; Waage, et al., 1989a and b;
Lieschke et al., 1989).
Patients and methods
The clinical study has been described in detail elsewhere
(O'Reilly et al., 1993). In brief, patients with advanced
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melanoma were eligible for entry into the trial. The drug
schedule consisted of FAA (LM 975) supplied by Lipha,
Lyons) 4.8 mg m-2 given over 1 h (Course A). After a 6 day
drug free interval, therapy with FAA was repeated as before
and, 1 h after, IL-2 (18 x 106 iu/m2/24 h) was given as a 5
day continuous infusion (Course B). Following a 48 h treat-
ment free interval the planned protocol was to repeat Course
B (Course C). Hydration and dose reduction were carried out
as reported (O'Reilly et al., 1993). Early in the study severe
clinical toxicity was noted shortly after the onset of Course
C. Severity of toxicity was graded from 1-4 on the basis of
hypotension. In the light of this toxicity the schedule was
modified and the day 15-18 IL-2 was omitted, however
toxicity continued to be observed in four out of seven
patients as previously reported.
Samples of blood were taken at regular intervals through-
out the study. Serum (or in a minority of cases plasma) was
separated within 1 h and stored frozen at -70'C until
required. Serial samples of serum were available on 12
patients, all of whom had dose modifications of IL-2 during
Course C and 5 of whom received no IL-2 at this time.
Cytokine assays
Bioassays were selected as the system of choice to ensure that
cytokine activity detected would be clinically relevant and
neutralisation by soluble receptors or specific antagonists
would not have to be excluded.
GM-CSF
GM-CSF was measured in the Mo7 proliferation assay. The
Mo7 cell line was derived from human acute megakaryo-
blastic leukaemia cells found initially to respond to IL-3 and
later GM-CSF (Avanzi et al., 1988), it also grows in response
to IL-4 and IL-9. In brief Mo7 cells were grown in 96 well
plates (Nunc) at 2 x 104 cells/well in RPMI 1640 medium
(Gibco) and 10% heat inactivated fetal calf serum (Gibco),
together with doubling dilutions in triplicate of test sera or
GM-CSF standard (Genetics Institute, Cambridge, Mass.)
for 72 h. 3H thymidine was added for the last 4 h of culture.
3H thymidine incorporation was determined by liquid scintil-
lation counting. In our hands Mo7 cells have a linear re-
sponse to GM-CSF in the range 0.1-2.5 units ml-l
(Haworth et al., 1991). In view of the possibility that Mo7
cells could proliferate in response to other cytokines (IL-3,
IL-4, IL-9), specificity for GM-CSF was shown in selected
samples by inhibition of Mo7 proliferation by polyclonal
anti-GM-CSF antibody (gift of Dr E. Abney, CXSRC).
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TNF
TNF was assayed as cytotoxicity against the mouse fibroblast
cell line WEHI 164 clone 13B (Espevik and Nissen-Meyer
1986). WEHI cells were cultered in 96 well plates at a con-
centration 2 x I04cells/well together with actinomycin D at a
concentration of 0.5 glg ml-' to increase the sensitivity of the
assay and doubling dilutions of test sera or standard
(Upjohn, Kalamazoo, Mich.), in DMEM (Northumbria
Biologicals) and 10% FCS. After 24 h of incubation, cell
viability was assayed using methyletrazolium (MTT) at a
final concentration of 0.5mgml1l for 4h and the colour
developed by overnight incubation with SDS/HC1. Assays
were carried out in duplicate and viability read on an Elisa
reader. The assay is sensitive over the range 15-500 pg ml-'
and detects TNF activity due to both TNFa and TNFP
(LT).
IL-6
IL-6 was assayed using the mouse hybridoma B9 prolifera-
tion assay (Aarden et al., 1987). B9 cells in log phase growth
were cultured in 96 well plates at 5 x 103 cells/well in RPMI
1640 and 10% FCS, together with doubling dilutions of test
sera or IL-6 standard (Interpharm). Initial studies suggested
that high concentrations of human sera could be inhibitory
to B9 cell growth. Heat activation of the sera (at 56°C for
30 min) was found to destroy the inhibitory capacity without
loss of added IL-6 activity. The cells were cultured for 72 h
and 3H thymidine was added for the last 4 h of the culture
period and thymidine incorporation assessed by liquid scintil-
lation counting.
IL-I
A selection of sera from a variety of time points (38 samples)
were tested for IL-l in the thymocyte proliferation assay.
Results
Using the above techniques we were able to detect changes in
the serum levels of TNF, IL-6 and GM-CSF in the treated
patients.
Course A
TNF activity was measured in four patients. Two out of four
patients had no initial activity, whereas two patients had
detectable levels (equivalent to 17, 39 pg ml-' of TNF).
These levels did not alter throughout the course. Baseline
IL-6 levels ranged from 0.02-0.16 uml'. One out of nine
patients studied throughout Course A showed a rise in IL-6
levels. A similar picture was seen with GM-CSF, where
baseline levels were always <0.1 uml-'.
Course B
The mean levels of TNF, IL-6, and GM-CSF during Course
B are shown in Figure 1. A total of 12 patients were studied
for a variable number of timepoints. In nine patients in
whom TNF activity was evaluated, seven had detectable
levels of activity between 8-96 h after the start of the treat-
ment. The individual maxima varied between
64-250 pg ml-'. A minimal rise in IL-6 levels was seen in
5/12 patients, the maximum detected activity being
0.4 uml-'. GM-CSF activity again showed a similar pattern
to IL-6. Samples taken late in the course (120 h) were only
available for assay in two cases but in both these samples
GM-CSF was detected (1.48; 2.0 u ml-') suggesting that
levels were still elevated at this time point. The results are
summarised in Table I.
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during Course B.
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Table I Mean, range and s.d. for IL-6, GM-CSF and TNF levels at time points
during Cource C
Time (h) IL-6 (um-') GM-CSF (uml-') TNF (pgmlh')
0 0.06 0.42 43.67 Mean
0.02-0.08 0.01 -1.72 30-60 Range
0.02 0.55 17.2 s.d.
8 8 6 Sample no.
2 3.18 3.25 74 Mean
0.04- 17.01 0.18- 11.84 38-105 Range
6.159 3.97 27.7 s.d.
8 8 4 Sample no.
4 32.7 2.14 69 Mean
0.19- 189 0.01 -6.64 24-120 Range
69.9 2.77 47.14 s.d.
8 8 5 Sample no.
6 4.86 2.08 43.67 Mean
0.31-9.9 0.01-6.60 18-75 Range
3.35 2.25 21.53 s.d.
7 7 6 Sample no.
24 0.53 0.43 32.5 Mean
0.02- 1.40 0.01-1.46 16-48 Range
0.496 0.487 13.01 s.d.
6 8 4 Sample no.
48 0.29 0.35 36.5 Mean
0.02-0.65 0.12-0.85 17-56 Range
0.284 0.35 27.6 s.d.
4 4 2 Sample no.1348 C. HAWORTH etal.
Course C
The results of the cytokine assays performed during Course
C are shown in Table I. (In three patients the IL-6 and
GM-CSF activity is available only as stimulation of
thymidine incorporation and the data are not incorporated
into the table or figures; they do however show a similar
pattern).
For all three cytokines there was a rise in activity following
the initiation of Course C and peaking between 2-6h of
treatment. The change in cytokine levels was shown in
patients regardless of whether IL-2 therapy was initially
included in the Course C treatment. (Figure 2). The cytokine
levels on the 12 patients for whom serial results are available
during Course C do not show any correlation with clinical
toxicity or IL-2 dose. Results from a representative patient
are shown in Figure 3, this patient received no IL-2 during
Course C and did not experience any toxicity.
In summary, during Course A (FAA alone) there was a
small rise in IL-6 and GM-CSF in one patient, the
significance ofwhich is uncertain. Modest elevations ofTNF,
GM-CSF and IL-6 are seen in some patients during Course
B (see Figure 1) but initiation of Course C results in a rapid
rise which is consistently detectable in IL-6 and GM-CSF
levels within 6 h of Course C therapy (Table I, Figure 2).
This rise appears to be independent of the presence of IL-2 in
the Course C schedule. These results suggest that FAA alone
can induce cytokine synthesis under certain conditions.
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during Course C in patients who received no IL-2 (U) or who
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Figure 3 Cytokine levels during Course C for one typical patient
who did not receive IL-2.
Discussion
Previous studies have shown that IL-2 therapy is associated
with induction of other cytokines which may reach detectable
levels in the circulation. TNF has been detected in associa-
tion with IL-2 therapy by some workers (Mier et al., 1988;
Pawelec et al., 1990) but not by others Ascensao et al., 1989).
Elevated levels of M-CSF (Sono et al., 1991) and Eo-CSF
(IL-5) (Nakamura et al., 1990) have been measured in pleural
exudate following intrapleural IL-2 therapy. Recently
Tritarelli et al. (1991) have demonstrated that a rise in cir-
culating haemopoietic progenitor cells, observed following a
5 day course of IL-2 may be related to a rise of IL-6 and
G-CSF during days 3-5 of the infusion. Unlike us, Tritarelli
et al., did not observe any elevation in GM-CSF during IL-2
therapy. This may reflect the differing sensitivities of the
immuno- and bio-assays. In the mouse FAA has been dem-
onstrated to induce the synthesis of mRNA for three cyto-
kines -TNFa, interferon and y interferon (Mahadevan et al.,
1990). TNFa was implicated in the anti-tumour action of
FAA in mouse by inhibition of the action against murine
colon carcinoma by anti-TNFa antibodies (Pratesi et al.,
1990). There has been no demonstrable anti-tumour effect in
man when FAA is given alone. One possible explanation of
this is that FAA is ineffective at stimulating release of
cytokines including TNFa in man. We have demonstrated
that the above schedule of IL-2 and FAA therapy is
associated with changing circulating levels of three cytokines
-TNF, GM-CSF, and IL-6, but not of IL-1, using bioassay
systems. Bioassays were used as this ensured that all
cytokines detected were physiologically relevant and were not
being neutralised in the sera by antagonists such as soluble
TNF receptors. It is possible that immunoreactive IL-1 is
present in the sera but that this is being neutralised by its
physiological antagonist IRAP.
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The evidence from the data in Course C suggests that these
cytokines can be induced by FAA following prior IL-2 and
FAA therapy, but not when it is given at the beginning of
the course. This indicates that the prior treatment has
induced responsiveness to FAA in the producer cells. How-
ever high serum levels of cytokines were detected in patients
in whom there was no objective tumour regression, suggest-
ing that other factors are important in tumour responsiveness
to FAA. We have only assayed a small number of the known
cytokines and it is possible that others are similarly
upregulated.
In addition FAA has been shown to induce nitric oxide
production in macrophages (Thomsen et al., 1992) and it is
interesting to note that in 11 out of 14 patients in whom
nitric oxide levels were measured peak levels were achieved
during the same period as high IL-6 and GM-CSF levels.
The patient numbers are small and although grade 3/4
hypotension occurred in many patients in the study after
Course C FAA, there is no apparent correlation in individual
patients between TNF, IL-6 or GM-CSF levels and clinical
toxicity. However further studies should clarify this. It is
possible that other cytokines are important in the toxicity
either wholly or in part by synergising with one or other of
those measured in the study, or that other patient variables
are important in determining toxicity.
TNF, together with IL-1, is a major proinflammatory
mediator which induces the synthesis of other cytokines. We
have shown that it plays a pivotal role in the induction of
IL-1 and GM-CSF in cultured synovial cells from patients
with rheumatoid arthritis (Brennan et al., 1989; Haworth et
al., 1991). We were therefore interested in assessing its role in
inducing further cytokines in this context. There is
insufficient data on patients' levels through Course B to allow
us to assess this as a prognostic indicator of high cytokine
levels during Course C, however there is no correlation
between TNF levels during course C and either IL-6 or
GM-CSF levels. There is however a clear association between
IL-6 and GM-CSF levels which suggests that they are
similarly regulated.
Which cells are producing these cytokines? The rise in
cytokine levels during Course C follows soon after the initia-
tion of treatment (FAA, with or without IL-2). Toxicity
(grade 3-4 hypotension) was observed in patients regardless
of IL-2 being included in Course C. It therefore appears that
FAA alone can result in cytokine release from cells which
have been activated by the previous IL-2 and FAA treat-
ment. IL-2 directly activates T lymphocytes, N.K. cells and
pre-activated monocytes, but may activate other cells
indirectly via intermediate cytokines e.g. TNF or a
interferon. As both IL-6 and GM-CSF are produced by a
variety of target cells (T cells, macrophages, fibroblasts and
endothelial cells) there is a similarly large pool of target cells
for the FAA action.
Further studies are necessary to understand the mechanism
of induction of these cytokines and their role in generating
toxicity or clinical response. Specific modification of their
effects e.g. by monoclonal antibodies or soluble receptors
may lead to more effective use of IL-2 in cancer therapy
either by enabling a reduction in toxicity and/or increased
therapeutic effectiveness. Neutralisation of TNF effect by
pentoxifylline (Alegre et al., 1991) or by anti-TNF monoc-
lonal antibodies (Ferran et al., 1991) has been demonstrated
to reduce toxicity associated with anti-CD3 therapy. In addi-
tion nitric oxide has been suggested to play a role as an
immune mediator (Kolb & Kolb-Bachofen, 1992) and the
inter-relationship between NO and cytokines in tumour
therapy should be more fully investigated.
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